StockData

Allarity Therapeutics vs Cardiff Oncology

ALLR and CRDF side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ALLR and CRDF compare

Cardiff Oncology is the larger company, worth 4.7 times as much as Allarity Therapeutics ($65.3M against $13.9M).

Cardiff Oncology scores higher on the StockData Score (7 against 1 for Allarity Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricALLRCRDF
Size and price
Market cap$13.9M$65.3M
Share price$0.872$0.839
Change, 1 year−22.1%−59.3%
Change, 5 years–−85.0%
Beta (5Y)1.111.58
Employees831
StockData Score
Total score17 (better)
Valuation score00
Growth score01 (better)
Performance score01 (better)
Health score15 (better)
Dividend score00
Valuation
P/S–128×
P/B3.9×2.5× (better)
Growth
Revenue growth (TTM)–−7.0%
Revenue growth, 5Y average–10.1%
Profitability
Operating margin–−8320%
Net margin–−7884%
Return on equity−157%−94.1% (better)
Return on invested capital−957%–
Financial health
Debt / equity5.90 (better)0.00
Interest coverage−10.1×–
Current ratio1.113.30 (better)
Altman Z-score−6.64 (better)−16.24
Piotroski F-score4 (better)1
Dividends and buybacks
Buyback yield6.4%–
Shareholder yield6.4% (better)0.00%
Ownership
Held by institutions8.1%24.2%
Held by insiders6.3%4.9%
Insider net buying, 12 months–$1.1M
Short interest, % of float1.5%16.6%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.